There is an unmet need to develop imaging methods for the early and objective assessment of breast tumors to therapy. 18 F]FLT (K i ) ranged from 0.6 to 10.4 Â 10 À4 and from 0 to 0.6 Â 10 À4 mL plasma cleared/s/mL tissue in tumor (29 regions, 15 patients) and normal tissues, respectively. Tumor K i and fractional retention of radiotracer determined by spectral analysis correlated with Ki-67 labeling index (r = 0.92, P < 0.0001 and r = 0.92, P < 0.0001, respectively). These correlations were superior to those determined by semiquantitative methods. We conclude that [ 18 F]FLT-positron emission tomography is a promising clinical tool for imaging cellular proliferation in breast cancer, and is most predictive when analyzed by graphical and spectral methods. (Cancer Res 2005; 65(21): 10104-12) 
Introduction
Breast cancer is the leading cause of cancer death in women from the industrialized world. In patients with large tumors (>3 cm), preoperative chemotherapy or hormonal therapy is increasingly used to reduce the size of the primary tumor mass and any occult metastases in order to improve survival and/or as part of breast conservation surgery. There is an unmet need to develop imaging methodologies that can enable early and objective assessment of response to such neoadjuvant therapies. Crosssectional imaging methodologies such as X-ray and computed tomography can give an indication of the sensitivity of tumors to treatment, but in most cases, only after several courses of treatment. Proliferation markers derived from tumor biopsies are both predictive of pathologic response and could measure disease outcome early enough (1-4 weeks) to allow treatment decisions to be altered (1) (2) (3) (4) (5) (6) (7) . The drawbacks for using biopsies include sampling error, invasiveness, and the inability to perform multiple repeat procedures. In this article, we report the clinical development of 3V -deoxy-3V - [ 18 F]fluorothymidine ([ 18 F]FLT)-positron emission tomography (PET) for noninvasively quantifying proliferation in patients with breast cancer. This imaging method is likely to be superior to biopsy methods because it can report on the whole (heterogeneous) tumor, nodal disease, and metastases, and is less invasive for response monitoring compared with multiple biopsies.
[ 18 F] FLT is a pyrimidine nucleoside that is a substrate for the cytoplasmic enzyme, thymidine kinase 1 (TK1; ref. 8) . TK1 phosphorylates [ 18 F]FLT into a highly charged product which is trapped and can be imaged using PET. A significant correlation between TK1 in breast tumors determined by immunohistochemistry and Ki-67 labeling index (Ki-67 LI) has been reported by He et al. (9) . The activity of TK1 is S phase-specific (10) (11) (12) (13) , it increases in S phase (14) and is targeted for degradation in late M phase (15) (16) (17) (18) , such that newly divided G 1 cells have low TK1 levels (19) . Our group has shown that TK1 and cofactor, ATP, regulate [
18 F]FLT uptake in tumors in vivo (20) . Furthermore, our preclinical studies show that [ 18 F]FLT-PET can be used to measure response to chemotherapy in mouse xenografts (21, 22) . In parallel with these encouraging preclinical studies, a number of groups are developing [ 18 F]FLT-PET clinically for imaging of cellular proliferation. Initial studies in lung cancer, colorectal cancer, and lymphoma (23) (24) (25) (26) (27) have shown high correlations between [ 18 F]FLT uptake and Ki-67 immunostaining of biopsy material. To date, no systematic evaluation of analytic methods for determining ''proliferation-related'' PET parameters in breast cancer has been done. As a prelude to the use of [ 18 F]FLT-PET to study drug response in patients, we have studied the kinetics of [ 18 F]FLT in tissues by PET and simultaneously in blood by gamma counting to allow a number of kinetic parameters to be determined. We have compared these kinetic parameters to Ki-67 LI to see how the parameters relate to proliferation.
Materials and Methods
Study design. The aim of the study was to determine parameters that reflect the delivery (K 1 ) and retention [rate constant for the net irreversible clearance of radiotracer from plasma to tissue (K i ), fractional retention of radiotracer in tissue at 90 minutes relative to that at 1 minute (FRT), standardized uptake value at 90 minutes (SUV 90 ), and area under the radioactive concentration versus time curve (AUC)] of [ 18 F]FLT in humans and to evaluate how these compare with proliferation as assessed by immunohistochemistry of biopsy material. To achieve this aim, we did PET scans on patients with locally advanced or metastatic epithelial breast cancer who were not receiving active treatment at the time of the study. Fifteen patients with 13 primary tumor areas, 6 nodal metastatic areas, and 1 pulmonary metastasis were studied; overall, multiple slices from 29 distinct tumor regions were studied by PET. Patients with histologically proven invasive breast cancer and measurable disease (z2.5 cm) with the site(s) of measurable disease outside the liver or bone marrow (as previous [ Positron emission tomography imaging. [ 18 F]FLT was synthesized by Hammersmith Imanet by radiofluorination of the 2,3V -anhydro-5V -O-(4,4V -dimethoxytrityl)-thymidine precursor using a method described previously (29) . PET scanning was done for 95 minutes after a single bolus i.v. injection of a tracer dose of [ 18 F]FLT [ranging between 153 and 380 MBq, specific activity 25-465 GBq/Amol, determined by high-performance liquid chromatography (HPLC)] over 30 to 60 seconds. All scans were done on an ECAT962/HR+ scanner (CTI/Siemens, Knoxville, TN), which allows simultaneous data acquisition to form 63 transaxial planes (axial field of view, 15.7 cm). Data were binned into 31 discrete time intervals of varying length (30 seconds Â 10, 60 seconds Â 5, 120 seconds Â 5, 180 seconds Â 5, 600 seconds Â6). From the PET image data, regions of interest on tumor and normal tissues (normal breast tissue) were defined manually using the Analyze image analysis software (Biomedical Imaging Resource, Mayo Foundation Rochester, MN). Normal lung tissue was used instead of normal breast tissue where there was no normal breast tissue in the field of view (as in the case of patient no. 2 with a lung metastasis, or in patient no. 10 with relapsed disease in the axilla).
Blood and metabolite analyses. In addition to the PET scanning, arterial blood sampling was done continuously for the first 10 minutes, discrete arterial samples (10 mL) were taken at baseline, 2. 30 ) was determined by reversed-phase HPLC with radiochemical detection. To determine total blood radioactivity, 1 mL each of blood and plasma were counted in a sodium iodide well counter (assembled in-house). Plasma samples (2 mL) were deproteinated by mixing with 5-fold of icecold acetonitrile (Fisher Scientific UK, Leicestershire, United Kingdom) and centrifuged at 3,000 Â g for 3 minutes at 4jC (Hettich, Scientific Laboratory Supplies Ltd., Nottingham, United Kingdom). The resulting supernatant containing the extracted radioactivity was concentrated by rotary evaporation (Heifdoff, LabPlant, Huddersfield, United Kingdom), resuspended in 3 mL of HPLC mobile phase and filtered using a 0.2 Am diameter filter (Acrodisc, VWR International Ltd., Leicestershire, United Kingdom). Aliquots (1 mL) of the filtrate were separated on a A-Bondapak C 18 column (300 Â 7.8 mm i.d., 10 Am particle size; Waters, Elstree, Hertfordshire, United Kingdom) with a mobile phase composed of 10 mmol/L potassium dihydrogen phosphate buffer (pH 4.0) and acetonitrile (85:15 v/v) delivered at a flow rate of 3 mL/min. The eluate was monitored for radioactivity with a gamma detector (Raytek, Sheffield, United Kingdom) linked to a personal computer-based integrator (Laura, Lablogic, Sheffield, United Kingdom) that enabled correction for [ 18 . SUV 90 was the SUV at the last time frame (m 2 /mL). For comparison, we also determined SUV 21.5 , the SUV at 21.5 minutes (m 2 /mL). AUC (m 2 /mL Â s) was calculated as the integral of all counts from 0 to 95 minutes. K i was determined by the modification of a graphical analysis first described by Herholz and Patlak (31) . The original Patlak model assumes that there is a single radiotracer and a single source for the radiotracer, the plasma. [ 18 F]FLT, however, undergoes a predominantly hepatic metabolism to a glucuronide, which is circulated in blood to all tissues and eliminated. Determination of K i for [
18 F]FLT, therefore, demands the use of an arterial plasma input function that is corrected for metabolites, as well as an algorithm that takes into account the contribution of metabolites to the exchangeable space within tissues (the metabolite does not contribute to the specific signal; glucuronidation occurs in the same position that is phosphorylated; ref. 7). K i was calculated according to the following equation at steady state (32):
where V is defined below, (7, 34, 35) . This method allows modeling of the relationship between parent plasma radioactivity and tissue radioactivity to obtain the unit impulse response function (IRF). This function is superior to tissue radioactivity per se as it takes into account the time-dependent contribution of radioactivity from plasma. In this case, tissue data can be expressed as:
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where n is the number of identifiable kinetic components, b is a constant chosen to describe the entire spectrum of expected kinetic behavior of the radiotracer from the slowest possible clearance k, to the fastest measurable dynamic (k < bi < 1), and a is the intensity of the kinetic component at bi.
The retention parameter, FRT, was defined as the IRF at 90 minutes relative to that at 1 minute.
Immunohistochemistry. To evaluate the relationship between PET parameters and direct measurement of proliferation, formalin-fixed tumor samples obtained from core biopsies within 3 months (median 18 days) preceding the PET scan were sectioned and immunostained with an antiKi-67 antibody, NCL-Ki-67-MM1 (Novocastra Laboratories, Newcastle upon Tyne, United Kingdom). The number of total and Ki-67-positive cells were manually counted in eight randomly selected fields of view using a BX51 Olympus microscope (Olympus Optical, Tokyo, Japan) at Â400 magnification and with the aid of Sigma Scan Pro 5 (Aspire Software International, Leesburg, VA). The Ki-67 LI was calculated as the ratio of the number of Ki-67-positive cells to the total number of cells.
Statistical analysis. A paired t test was used to assess the difference between tumor and normal tissue data. The association between PET parameters and Ki-67 LI was determined by calculating the Pearson correlation coefficient (95% confident; two-tailed). P V 0.05 was considered significant. Statistical analysis was done using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).
Results

Visual distribution of 3V -deoxy-3V -[
18 F]fluorothymidine in the body. All of the patients had measurable disease in the breast or axilla, except for patient no. 2, who had a secondary lung metastasis ( from breast cancer). The mean dose of activity (Fig. 1A) . The high signal intensity in the liver and vertebrae has been attributed to glucuronidation and bone marrow cell proliferation, respectively (36) . [ 18 F]FLT tumor localization was lower in an inflammatory tumor ( Fig. 1D and G) compared with a lobular carcinoma (Fig. 1B and E) , which in turn had lower [ 18 F]FLT uptake than a ductal carcinoma (Fig. 1C and F) . In large tumors (>5 cm), there was marked heterogeneity; regions of obvious necrosis were excluded from the analysis. Radiotracer localization also differed between primary tumors and metastases from the same patient. Localization of radioactivity in normal tissues such as breast and lung was generally low.
Quantitative 3V -deoxy-3V -[ 18 F]fluorothymidine-positron emission tomography kinetic parameters in tumors and normal tissues. Quantification of tissue kinetic parameters allows the generation of physiologic information of universal comprehension. Using arterial plasma samples from five patients, we were able to biochemically confirm that the sole plasma metabolite detected by HPLC was a glucuronide (Table 1 ; Fig. 2 ). We have determined parameters that describe delivery and retention of [ from the blood (transported from the liver) can occupy an exchangeable space but does not contribute to the specific signal derived from the phosphorylation of Fig. 3B ). Using the modified Patlak approach, a linear phase of the curve was discernible at steady state (Fig. 3C) , indicating that there was unidirectional uptake of the radiotracer; the slope, K i , was higher in tumor than in normal tissues. The spectral model also fitted the data and showed that there was a retention component in tumor but less so in normal breast (asymptotic nature of the IRF; Fig. 3D ). As seen in Fig. 3E , spectral analysis shows all the dynamics, fast, and slow components. A trapped component is only seen in tumor and not normal breast, corroborating the low K i of normal breast (Table 2 ; Fig. 3E) .
A summary of the parameters from all 29 individual tumor sites from 15 patients is shown in Table 2 . The delivery and retention of [ 18 F]FLT were higher in tumors than in normal tissues as assessed by paired t test [K i (P < 0.0001), SUV 21.5 (P < 0.0001), SUV 90 (P < 0.0001), AUC (P < 0.0001), FRT (P < 0.0001), and the delivery of F]FLT is to be used as a surrogate marker of cell proliferation, it was important to examine the association between its kinetic parameters and a standard measure of proliferation, Ki-67 LI. Of particular interest are associations with the kinetic parameters that describe retention because these are related to the phosphorylation of the radiotracer by TK1. Suitable histology was available in 12 of the 15 patients. An example of the difference in retention of [ 18 F]FLT between tumors with low (patient nos. 1 and 11) and high (patient no. 4) Ki-67 LI is shown in Fig. 1 . A strong correlation was found between Ki-67 LI and K i (r = 0.92, P < 0.0001), FRT (r = 0.92, P < 0.0001), SUV 21.5 (r = 0.71, P = 0.0098), SUV 90 (r = 0.79, P = 0.0022), and AUC (r = 0.76, P = 0.004; Fig. 4 ). There was a nonsignificant correlation between Ki-67 LI and K 1 (r = 0.28, P = 0.38). ]FLT-PET images showed high tumor-to-background contrast. Uptake was also seen in the liver and bone marrow due to catabolism of the radiotracer, as well as its uptake by the proliferating bone marrow cells (28, 36) .
Using new and previously described analytic methodologies, we measured the delivery and retention of the radiotracer in tumors À3 mL plasma/s/mL tissue). Given the low blood flow in breast tumors, it remains to be seen how generalizable the conclusion from the work will be for tumors with higher blood flow. For comparisons with blood flow, estimations of K 1 in this study may be suboptimal given the large time frames of 30 seconds at the start of the dynamic imaging protocol (designed to improve the signal to noise ratio). This may explain the large variance in K 1 values.
Because the proliferation-specific signal for [ (38) . In our breast cancer studies, this leads to overestimation of K i by 12.5% (data not shown), although the correlation with Ki-67 (r = 0.94, P < 0.0001) does not change (Fig. 4E) . Ignoring any contribution from the metabolites underestimates K i by 16.9%, although this does not affect the correlation with Ki-67 either (r = 0.94, P < 0.0001; Fig. 4F ). The small difference in K i values when exchangeable space is taken into account (12.5%) indicates that the contribution to the exchangeable space by labeled metabolites is not substantial, supporting the notion that glucuronides are rapidly eliminated. These findings also suggest that correction of data for metabolites may not be required for larger scale clinical studies in the future.
The semiquantitative parameters, SUV 90 and AUC, were also highly correlated with Ki-67. SUV is the parameter which has been used by most investigators in other tumor types including lung and colorectal cancer, and in general, correlation coefficients of 0.7 to 0.92 have been reported (23, 24, 26, 27 (39) . In that study, there was a lack of correlation between Ki-67 and [
18 F]FLT-derived SUV. The scanning protocol in that case, however, was different and the SUV value was not corrected for body surface area. SUV normalized to lean body mass or body surface area eliminates the weight dependence of SUV (40, 41 
